Kamada (KMDA) Other Non-Current Liabilities (2021 - 2026)

Kamada (KMDA) posted quarterly Other Non-Current Liabilities of $29.9 million for Q1 2026, down 9.29% year-on-year from $33.0 million in Q1 2025, and down 0.62% on a QoQ basis from $30.1 million in Q4 2025.

Kamada (KMDA) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

Kamada (KMDA) has reported Other Non-Current Liabilities for 6 consecutive years, with $29.9 million the latest figure, recorded in Q1 2026.

  • Quarterly Other Non-Current Liabilities fell 9.29% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.9 million (down 9.29% YoY) and the FY2025 annual result came in at $30.1 million, down 8.24% from the prior year.
  • Other Non-Current Liabilities declined to $29.9 million in Q1 2026 per KMDA's latest filing, from $30.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for KMDA reached as high as $42.5 million in Q1 2022 and fell as low as $37280.0 in Q1 2023.
  • A 5-year average of $30.8 million and a median of $34.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 99.91% — and 2024, when it jumped 93360.3%.
  • Year by year, Other Non-Current Liabilities stood at $37.3 million in 2022, then decreased by 7.85% to $34.4 million in 2023, then slipped by 4.55% to $32.8 million in 2024, then decreased by 8.24% to $30.1 million in 2025, then fell by 0.62% to $29.9 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $29.9 million, $30.1 million, and $32.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Kamada 401.22 Mn 328.07 Mn 19.12 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 29.93 Mn
Dec 31, 2025 30.11 Mn
Sep 30, 2025 32.54 Mn
Jun 30, 2025 32.78 Mn
Mar 31, 2025 32.99 Mn
Dec 31, 2024 32.82 Mn
Sep 30, 2024 34.12 Mn
Jun 30, 2024 34.24 Mn
Mar 31, 2024 34.84 Mn
Dec 31, 2023 34.38 Mn
Sep 30, 2023 36.48 Mn
Jun 30, 2023 36.51 Mn
Mar 31, 2023 37,280.00
Dec 31, 2022 37.31 Mn
Sep 30, 2022 39,915.00
Jun 30, 2022 41.30 Mn
Mar 31, 2022 42.53 Mn
Dec 31, 2021 43.93 Mn